Peptor Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 53

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $69.7M

Peptor General Information

Description

Developer of products to treat autoimmune diseases. The company develops small cyclical analogues of peptide loop drugs to treat cancer, bacterial and fungal infections, autoimmune diseases, multiple sclerosis and other disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Kiryat Weizmann
  • Rehovot 78326
  • Israel
+972
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Kiryat Weizmann
  • Rehovot 78326
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Peptor Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 17-May-2004 $69.7M Completed Generating Revenue
7. Later Stage VC 01-Nov-1999 Completed Generating Revenue
6. Later Stage VC 29-Sep-1998 Completed Startup
5. IPO 25-Jun-1997 Cancelled Startup
4. Early Stage VC 01-May-1996 Completed Startup
3. Early Stage VC 01-Nov-1995 Completed Startup
2. Early Stage VC 01-Dec-1993 $10M $11M Completed Startup
1. Seed Round 01-May-1993 $1M $1M Completed Startup
To view Peptor’s complete valuation and funding history, request access »

Peptor Patents

Peptor Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2005072056-A2 Hsp therapy in conjunction with a low antigenicity diet Inactive 28-Jan-2004
WO-2005072056-A3 Hsp therapy in conjunction with a low antigenicity diet Inactive 28-Jan-2004
WO-2004110337-A2 Cell permeable conjugates of peptides for inhibition of protein kinases Inactive 12-Jun-2003
WO-2004110337-A3 Cell permeable conjugates of peptides for inhibition of protein kinases Inactive 12-Jun-2003
WO-2004098489-A2 Compositions and methods for modulation of specific epitopes of hsp60 Inactive 12-May-2003 A61K38/1709
To view Peptor’s complete patent history, request access »

Peptor Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Peptor Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ampal Venture Capital Minority
Carlyle AlpInvest PE/Buyout Minority
Citibank Corporation Minority
Clal Biotechnology Industries Venture Capital Minority
David Blech & Co Other Minority
You’re viewing 5 of 11 investors. Get the full list »

Peptor FAQs

  • When was Peptor founded?

    Peptor was founded in 1993.

  • Where is Peptor headquartered?

    Peptor is headquartered in Rehovot, Israel.

  • What is the size of Peptor?

    Peptor has 53 total employees.

  • What industry is Peptor in?

    Peptor’s primary industry is Biotechnology.

  • Is Peptor a private or public company?

    Peptor is a Private company.

  • What is the current valuation of Peptor?

    The current valuation of Peptor is .

  • What is Peptor’s current revenue?

    The current revenue for Peptor is .

  • How much funding has Peptor raised over time?

    Peptor has raised $63.5M.

  • Who are Peptor’s investors?

    Ampal, Carlyle AlpInvest, Citibank, Clal Biotechnology Industries, and David Blech & Co are 5 of 11 investors who have invested in Peptor.

  • When was Peptor acquired?

    Peptor was acquired on 17-May-2004.

  • Who acquired Peptor?

    Peptor was acquired by Evotec International.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process